Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: Methodology and external validation

被引:8
|
作者
Vranckx, Pascal [1 ]
McFadden, Eugene [2 ]
Cutlip, Donald E. [3 ]
Mehran, Roxana [4 ]
Swart, Michael [1 ]
Kint, P. P. [1 ]
Zijlstra, Felix [7 ]
Silber, Sigmund [5 ]
Windecker, Stephan [6 ]
Serruys, Patrick W. C. J. [7 ]
机构
[1] Cardialysis Clin Res Management & Core Labs, Rotterdam, Netherlands
[2] Cork Univ Hosp, Dept Intervent Cardiol, Cork, Ireland
[3] Harvard Univ, Sch Med, Harvard Clin Res Inst, Boston, MA USA
[4] Mt Sinai Med Ctr, Zena & Michael A Weiner Cardiovasc Inst, New York, NY USA
[5] Isar, Ctr Heart, Munich, Germany
[6] Univ Hosp Bern, CH-3010 Bern, Switzerland
[7] Erasmus MC, Univ Med Ctr Rotterdam, Thoraxctr, Dept Intervent Cardiol, Rotterdam, Netherlands
关键词
Adjudication; Clinical event committee; Endpoints; Validation; PTCA; Stenting; MYOCARDIAL-INFARCTION; TRIALS; INTERVENTION; DEFINITIONS;
D O I
10.1016/j.cct.2012.08.012
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Globalisation in coronary stent research calls for harmonization of clinical endpoint definitions and event adjudication. Little has been published about the various processes used for event adjudication or their impact on outcome reporting. Methods and results: We performed a validation of the clinical event committee (CEC) adjudication process on 100 suspected events in the RESOLUTE All-corners trial (Resolute-AC). Two experienced Clinical Research Organisations (CRO) that had already extensive internal validation processes in place, participated in the study. After initial adjudication by the primary-CEC, events were cross-adjudicated by an external-CEC using the same definitions. Major discrepancies affecting the primary end point of target-lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI), or clinically-indicated target-lesion revascularization (CI-TLR), were analysed by an independent oversight committee who provided recommendations for harmonization. Discordant adjudications were reconsidered by the primary CEC. Subsequently, the RAC database was interrogated for cases that based on these recommendations merited re-adjudication and these cases were also re-adjudicated by the primary CEC. Final discrepancies in adjudication of individual components of TLF occurred in 7 out of 100 events in 5 patients. Discrepancies for the (hierarchical) primary endpoint occurred in 5 events (2 cardiac deaths and 3 TV-MI). After application of harmonization recommendations to the overall RAC population (n = 2292), the primary CEC adjudicated 3 additional clinical-TLRs and considered 1 TV-MI as no event. Conclusions: A harmonization process provided a high level of concordance for event adjudication and improved accuracy for final event reporting. These findings suggest it is feasible to pool clinical event outcome data across clinical trials even when different CECs are responsible for event adjudication. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [1] External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial
    Ono, Masafumi
    Kawashima, Hideyuki
    Hara, Hironori
    Gamal, Amr
    Wang, Rutao
    Gao, Chao
    O'Leary, Neil
    Soliman, Osama
    Piek, Jan J.
    Van Geuns, Robert-Jan
    Juni, Peter
    Hamm, Christian W.
    Valgimigli, Marco
    Vranckx, Pascal
    Windecker, Stephan
    Steg, Philippe Gabriel
    Fox, Keith A. A.
    Onuma, Yoshinobu
    Serruys, Patrick W.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 98 (04) : E513 - E522
  • [2] 1-Year Clinical Performance of COMBO Stent Versus Xience Stent in All-Comers Patients With Coronary Artery Disease
    Kalkman, Deborah N.
    Tijssen, Ruben Y. G.
    Kraak, Robin P.
    Woudstra, Pier
    Beijk, Marcel A.
    Tijssen, Jan G. P.
    Piek, Jan J.
    Henriques, Jose P. S.
    de Winter, Robbert J.
    Wykrzykowska, Joanna J.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (01) : 102 - 103
  • [3] Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial
    Saito, Yuichi
    Wijns, William
    Baumbach, Andreas
    Xu, Bo
    Kelbaek, Henning
    van Royen, Niels
    Zheng, Ming
    Knaapen, Paul
    Slagboom, Ton
    Johnson, Tom
    Vlachojannis, Georgios
    Holmvang, Lene
    Janssens, Luc
    Ochala, Andrzej
    Brugaletta, Salvatore
    Anderson, Richard
    Rittger, Harald
    Berti, Sergio
    Barbato, Emanuele
    Toth, Gabor
    Maillard, Luc
    Valina, Christian
    Buszman, Pawel
    Thiele, Holger
    Lansky, Alexandra
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (13) : B286 - B286
  • [4] Clinical outcomes of an ultra-thin strut sirolimus-eluting stent with biodegradable polymer in all-comers patients undergoing coronary intervention
    Menown, I. B. A.
    De Silva, R.
    Mitra, R.
    Balachandran, K.
    More, R.
    Spyrou, N.
    Zaman, A.
    Raja, Y.
    Tulwar, S.
    Sinha, M.
    Glover, J.
    Clifford, P.
    Ordoubadi, F.
    Elghamaz, A.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 1744 - 1744
  • [5] Shockwave Intravascular Lithotripsy in all-comers with resistant de novo calcified coronary disease or stent underexpansion: Growing evidence
    Kassimis, George
    Karamasis, Grigoris, V
    [J]. KARDIOLOGIA POLSKA, 2023, 81 (09) : 847 - 849
  • [6] The Real World Experience of the Biodegradable Polymer-Coated Sirolimus-Eluting Coronary Stent System: Results From an "All-Comers" Clinical Experience
    Rajasekhar, D.
    Vanajakshamma, V.
    Shashank, C.
    Srinivasakumar, M. L.
    Sivasankara, C.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2016, 88 (03) : E93 - E98
  • [7] Clinical outcomes of an ultrathin-strut sirolimus-eluting stent in all-comers population: Thailand Orsiro registry
    Suwannasom, Pannipa
    Athiksakul, Siriporn
    Thonghong, Tasalak
    Lertsuwunseri, Vorarit
    Chaipromprasit, Jarkarpun
    Srimahachota, Suphot
    Udayachalerm, Wasan
    Kuanprasert, Srun
    Buddhari, Wacin
    [J]. BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [8] Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective all-comers registry
    Ananthakrishna, Rajiv
    Kristanto, William
    Liu, Li
    Chan, Siew-Pang
    Loh, Poay Huan
    Tay, Edgar L.
    Chan, Koo Hui
    Chan, Mark Y.
    Lee, Chi-Hang
    Low, Adrian F.
    Tan, Huay Cheem
    Loh, Joshua P.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2018, 92 (06) : 1097 - 1103
  • [9] Contemporary indications, dual antiplatelet therapy strategies and clinical outcomes for a polymer-free biolimus A9-coated stent: the all-comers FREEDOM registry
    Gallone, G.
    D'Ascenzo, F.
    Di Biasi, M. D.
    Latini, R. A.
    Vicinelli, P.
    Poli, A.
    Boccuzzi, G.
    Gagnor, A.
    Gaido, L.
    Cerrato, E.
    Varbella, F.
    Rinaldi, M.
    Ielasi, A.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 1764 - 1764
  • [10] Comparison of the clinical performance between COMBO and Xience stent at one year follow-up in all-comers patients
    Kalkman, Deborah
    Tijssen, Ruben
    Elias, Joelle
    van Dongen, Ivo M.
    Kraak, Robin
    Woudstra, Pier
    Beijk, M.
    Tijssen, Jan
    Piek, Jan
    Henriques, Jose P. S.
    de Winter, Robbert
    Wykrzykowska, Joanna
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (18) : B175 - B176